tinnitus; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of tinnitus in a male patient who received Herpes zoster (Shingrix) for prophylaxis. In OCT-2024, the patient received the 1st dose of Shingrix. In DEC-2024, 2 months after receiving Shingrix, the patient experienced tinnitus (Verbatim: tinnitus). The outcome of the tinnitus was unknown. It was unknown if the reporter considered the tinnitus to be related to Shingrix. It was unknown if the company considered the tinnitus to be related to Shingrix. Additional Information: GSK Receipt Date: 09-JAN-2025 Patient DOB (date of birth) and initials were not available. The patient developed tinnitus 2 months after receiving the Shingrix.